Skip to main content

Brain Metastases: Introduction

  • Chapter
  • First Online:
Radiotherapy in Managing Brain Metastases

Abstract

Brain metastases are often associated with a poor prognosis; however, with earlier detection and increasingly available therapies, including wider use of stereotactic radiosurgery and targeted therapies, the prognosis appears to be improving. This chapter reviews the epidemiology, diagnosis, and prognostic systems for brain metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Jyoti B, Alam A, Hofer S, Brada M. Brain metastases. In: Lisak R, Truong D, Carroll W, Bhidarasiri R, eds. International neurology. 2nd ed. Hoboken, NJ: Wiley; 2016.

    Chapter  Google Scholar 

  2. Stelzer KJ. Epidemiology and prognosis of brain metastases. Surg Neurol Int. 2013;4(Suppl 4):S192–202.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Nayak L, Lee EQ, Wen P. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48–54.

    Article  PubMed  Google Scholar 

  4. Tabouret E, Chinot O, Metellus P, et al. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012;32:4655–62.

    PubMed  Google Scholar 

  5. Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. 2011;22:1–6.

    Article  PubMed  Google Scholar 

  6. Graus F, Walker RW, Allen JC. Brain metastases in children. J Pediatr. 1983;103(4):558.

    Article  PubMed  CAS  Google Scholar 

  7. Bouffet E, Doumi N, Thiesse P, Mottolese C, Jouvet A, Lacroze M, et al. Brain metastases in children with solid tumors. Cancer. 1997;79(2):403–10.

    Article  PubMed  CAS  Google Scholar 

  8. Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer. 2010;116(21):5038–46.

    Article  PubMed  Google Scholar 

  9. Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB, Aquino SL. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non–small cell lung cancer. J Thorac Oncol. 2006;1(3):205–10.

    Article  PubMed  Google Scholar 

  10. Aupérin A, Arriagada R, Pignon J-P, Le Péchoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–84.

    Article  PubMed  Google Scholar 

  11. Hochstenbag M, Twijnstra A, Wilmink J, Wouters E, Ten Velde GPM. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neuro-Oncol. 2000;48(3):243–8.

    Article  CAS  Google Scholar 

  12. Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol. 2004;15(11):1640–4.

    Article  PubMed  CAS  Google Scholar 

  13. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nole F, Thurlimann B, et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol. 2001;12(3):353–6.

    Article  PubMed  CAS  Google Scholar 

  14. Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat. 2012;136(1):153–60.

    Article  PubMed  Google Scholar 

  15. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006;17(6):935–44.

    Article  PubMed  CAS  Google Scholar 

  16. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13(6):1648–55.

    Article  PubMed  CAS  Google Scholar 

  17. Wronski M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology. 1996;47(2):187–93.

    Article  PubMed  CAS  Google Scholar 

  18. Mongan JP, Fadul CE, Cole BF, Zaki BI, Suriawinata AA, Ripple GH, et al. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer. 2009;8(2):100–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Daryanani D, Plukker JT, de Jong MA, Haaxma-Reiche H, Nap R, Kuiper H, et al. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res. 2005;15(2):119–24.

    Article  PubMed  Google Scholar 

  20. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93(1):9–18.

    Article  PubMed  CAS  Google Scholar 

  21. Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control. 2009;16(3):248–55.

    Article  PubMed  Google Scholar 

  22. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neuro-Oncol. 2005;75(1):5–14.

    Article  Google Scholar 

  23. Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol. 1988;45(7):741–4.

    Article  PubMed  CAS  Google Scholar 

  24. Hwang TL, Close TP, Grego JM, Brannon WL, Gonzales F. Predilection of brain metastasis in gray and white matter junction and vascular border zones. Cancer. 1996;77(8):1551–5.

    Article  PubMed  CAS  Google Scholar 

  25. Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol. 1992;31(3):268–73.

    Article  PubMed  CAS  Google Scholar 

  26. Sneed PK, Kased N, Huang K, Rubenstein JL. Chapter 52: brain metastases and neoplastic meningitis. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, WG MK, editors. Clinical oncology. Philadelphia: Churchill Livingstone; 2008. p. 827–41.

    Google Scholar 

  27. Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993;43(9):1678–83.

    Article  PubMed  CAS  Google Scholar 

  28. Nowosielski M, Radbruch A. The emerging role of advanced neuroimaging techniques for brain metastases. Chin Clin Oncol. 2015;4(2):23.

    PubMed  Google Scholar 

  29. Bashour SI, William WN, Patel S, Rao G, Strom E, McAleer MF, et al. Brain metastasis from solid tumors. In: Brain Metastases from Primary Tumors: Epidemiology, Biology, and Therapy. Vol. 2. Cambridge, MA: Elsevier; 2015.

    Chapter  Google Scholar 

  30. Venur VA, Ahluwalia MS. Prognostic scores for brain metastasis patients: use in clinical practice and trial design. Chin Clin Oncol. 2015;4(2):18.

    PubMed  Google Scholar 

  31. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.

    Article  CAS  PubMed  Google Scholar 

  32. Videtic GM, Adelstein DJ, Mekhail TM, Rice TW, Stevens GH, Lee SY, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for small-cell lung cancer-only brain metastases. Int J Radiat Oncol Biol Phys. 2007;67(1):240–3.

    Article  PubMed  Google Scholar 

  33. Weltman E, Salvajoli JV, Brandt RA, de Morais Hanriot R, Prisco FE, Cruz JC, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys. 2000;46(5):1155–61.

    Article  PubMed  CAS  Google Scholar 

  34. Nieder C, Mehta MP. Prognostic indices for brain metastases–usefulness and challenges. Radiat Oncol. 2009;4:10.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lorenzoni J, Devriendt D, Massager N, David P, Ruiz S, Vanderlinden B, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004;60(1):218–24.

    Article  PubMed  Google Scholar 

  36. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.

    Article  PubMed  Google Scholar 

  37. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510–4.

    Article  PubMed  Google Scholar 

  38. Golden DW, Lamborn KR, McDermott MW, Kunwar S, Wara WM, Nakamura JL, et al. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg. 2008;109(Suppl):77–86.

    Article  PubMed  Google Scholar 

  39. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655–61.

    Article  PubMed  Google Scholar 

  40. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972–7.

    Article  PubMed  Google Scholar 

  41. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24(36):5658–63.

    Article  PubMed  CAS  Google Scholar 

  42. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge RJC. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006;107(4):696–704.

    Article  PubMed  Google Scholar 

  43. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):2111–7.

    Article  PubMed  Google Scholar 

  44. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71.

    Article  PubMed  CAS  Google Scholar 

  45. Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis. 2015;32(7):729–37.

    Article  PubMed  CAS  Google Scholar 

  46. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. The effect of gene alterations and tyrosine kinase inhibition on survival and cause of death in patients with adenocarcinoma of the lung and brain metastases. Int J Radiat Oncol Biol Phys. 2016;96(2):406–13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72.

    Article  PubMed  Google Scholar 

  48. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698–705.

    Article  PubMed  Google Scholar 

  49. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827–31.

    Article  PubMed  Google Scholar 

  50. Nieder C, Hintz M, Oehlke O, Bilger A, Grosu AL. Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA). Radiat Oncol. 2017;12(1):107.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Hochmair M. Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from brain metastases and/or leptomeningeal disease. Target Oncol. 2018;13(3):269–85.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36(26):2702–9.

    Article  PubMed  CAS  Google Scholar 

  53. Martinez P, Mak RH, Oxnard GR. Targeted therapy as an alternative to whole-brain radiotherapy in EGFR-mutant or ALK-positive non-small-cell lung cancer with brain metastases. JAMA Oncol. 2017;3(9):1274–5.

    Article  PubMed  Google Scholar 

  54. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687–96.

    Article  PubMed  Google Scholar 

  55. Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, et al. The prognostic value of BRAF, C-KIT, and NRAS mutations in melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys. 2017;98(5):1069–77.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, et al. Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys. 2017;99(4):812–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Long GV, Margolin KA. Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. Am Soc Clin Oncol Educ Book. 2013;33(1):393–8.

    Article  Google Scholar 

  58. Wolf A, Zia S, Verma R, Pavlick A, Wilson M, Golfinos JG, et al. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neuro-Oncol. 2016;127(3):607–15.

    Article  CAS  Google Scholar 

  59. Juloori A, Miller JA, Parsai S, Kotecha R, Ahluwalia MS, Mohammadi AM, et al. Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases. J Neurosurg. 2019;1(aop):1–9.

    Google Scholar 

  60. Ayala-Peacock DN, Attia A, Braunstein SE, Ahluwalia MS, Hepel J, Chung C, et al. Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram. J Neuro-Oncol. 2017;135(2):403–11.

    Article  Google Scholar 

  61. Routman DM, Bian SX, Diao K, Liu JL, Yu C, Ye J, et al. The growing importance of lesion volume as a prognostic factor in patients with multiple brain metastases treated with stereotactic radiosurgery. Cancer Med. 2018;7(3):757–64.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Woody NM, Greer MD, Reddy CA, Videtic GMM, Chao ST, Murphy ES, et al. Validation of the disease-specific GPA for patients with 1 to 3 synchronous brain metastases in newly diagnosed NSCLC. Clin Lung Cancer. 2018;19(1):e141–e7.

    Article  PubMed  Google Scholar 

  63. Miller JA, Bennett EE, Xiao R, Kotecha R, Chao ST, Vogelbaum MA, et al. Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys. 2016;96(5):1060–9.

    Article  PubMed  Google Scholar 

  64. Kang J, Rancati T, Lee S, Oh JH, Kerns SL, Scott JG, et al. Machine learning and radiogenomics: lessons learned and future directions. Front Oncol. 2018;8:228.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Kotecha R, Vogel S, Suh JH, Barnett GH, Murphy ES, Reddy CA, et al. A cure is possible: a study of 10-year survivors of brain metastases. J Neuro-Oncol. 2016;129(3):545–55.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Samuel T. Chao .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Naik, M., Canavan, J.F., Chao, S.T. (2020). Brain Metastases: Introduction. In: Yamada, Y., Chang, E., Fiveash, J., Knisely, J. (eds) Radiotherapy in Managing Brain Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-43740-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-43740-4_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-43739-8

  • Online ISBN: 978-3-030-43740-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics